Anavex Life Sciences Corp (AVXL)

[Gator328]

Who cares if they write hit pieces? The only opinions that matter are the FDA experts. A well-timed hit piece full of slanted information may have a short-term adverse effect on the share price, but as long as Anavex isn't trying to raise more cash it doesn't really matter to anyone other than traders looking for a quick exit.

Before Jesse B, it was some other Twitter scientist. I can't remember her name. Before her, it was Nathan Michaud, and before him, Jean Fonteneau. Anavex investors should be used to these types by now and factor their influence into the short-term price action.

My fear is that healthcare insurers will be initially reluctant to pay for Blarcamesine.